Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical...
24 insider purchases on record · latest filing 2025-12-15.
Insiders have also filed 10 sale transactions at BMEA.